The potential role of lonidamine (LND) in the treatment of malignant glioma - Phase II study

Carmine M. Carapella; Marco G. Paggi; Fabio Cattani; Giovanni B. Ciottoli; Aristide Floridi; Bruno Iandolo; Laura Raus; Antonio Riccio; Antonio Caputo

doi:10.1007/BF00149384

The potential role of lonidamine (LND) in the treatment of malignant glioma - Phase II study

Carmine M. Carapella, Marco G. Paggi, Fabio Cattani, Giovanni B. Ciottoli, Aristide Floridi, Bruno Iandolo, Laura Raus, Antonio Riccio, Antonio Caputo

Istituto Regina Elena

Research output: Contribution to journal › Article › peer-review

Abstract

Up-to-date unsatisfactory results obtained in multimodality treatments of malignant glioma have prompted the research of new therapeutic modalities with 'unconventional' modes of action. Lonidamine (LND) is a drug which reduces aerobic glycolytic activity in both human and experimental tumors. This effect mainly depends on the inhibition of mitochondrially-bound hexokinase (HK) which is present in large amounts in malignant cells. A Phase II study was conducted on patients with recurrent glioma; 12 patients were admitted to the study. Clinical side effects were moderate, necessitating a reduction of the dosage in only 1 case. The objective results were evaluated according to the indications of Levin. 2 responders and 3 cases of stable disease were observed out of 10 evaluable patients. The potential value of this new drug is discussed.

Original language	English
Pages (from-to)	103-108
Number of pages	6
Journal	Journal of Neuro-Oncology
Volume	7
Issue number	1
DOIs	https://doi.org/10.1007/BF00149384
Publication status	Published - May 1989

Keywords

brain tumor metabolism
Lonidamine
malignant glioma

ASJC Scopus subject areas

Neuroscience(all)
Oncology
Clinical Neurology
Cancer Research

Access to Document

10.1007/BF00149384

Fingerprint Dive into the research topics of 'The potential role of lonidamine (LND) in the treatment of malignant glioma - Phase II study'. Together they form a unique fingerprint.

Cite this

The potential role of lonidamine (LND) in the treatment of malignant glioma - Phase II study. / Carapella, Carmine M.; Paggi, Marco G.; Cattani, Fabio; Ciottoli, Giovanni B.; Floridi, Aristide; Iandolo, Bruno; Raus, Laura; Riccio, Antonio; Caputo, Antonio.

In: Journal of Neuro-Oncology, Vol. 7, No. 1, 05.1989, p. 103-108.

Research output: Contribution to journal › Article › peer-review

@article{8929ef87f8104a3bbf566375e70d1797,

title = "The potential role of lonidamine (LND) in the treatment of malignant glioma - Phase II study",

abstract = "Up-to-date unsatisfactory results obtained in multimodality treatments of malignant glioma have prompted the research of new therapeutic modalities with 'unconventional' modes of action. Lonidamine (LND) is a drug which reduces aerobic glycolytic activity in both human and experimental tumors. This effect mainly depends on the inhibition of mitochondrially-bound hexokinase (HK) which is present in large amounts in malignant cells. A Phase II study was conducted on patients with recurrent glioma; 12 patients were admitted to the study. Clinical side effects were moderate, necessitating a reduction of the dosage in only 1 case. The objective results were evaluated according to the indications of Levin. 2 responders and 3 cases of stable disease were observed out of 10 evaluable patients. The potential value of this new drug is discussed.",

keywords = "brain tumor metabolism, Lonidamine, malignant glioma",

author = "Carapella, {Carmine M.} and Paggi, {Marco G.} and Fabio Cattani and Ciottoli, {Giovanni B.} and Aristide Floridi and Bruno Iandolo and Laura Raus and Antonio Riccio and Antonio Caputo",

year = "1989",

month = may,

doi = "10.1007/BF00149384",

language = "English",

volume = "7",

pages = "103--108",

journal = "Journal of Neuro-Oncology",

issn = "0167-594X",

publisher = "Springer New York LLC",

number = "1",

}

TY - JOUR

T1 - The potential role of lonidamine (LND) in the treatment of malignant glioma - Phase II study

AU - Carapella, Carmine M.

AU - Paggi, Marco G.

AU - Cattani, Fabio

AU - Ciottoli, Giovanni B.

AU - Floridi, Aristide

AU - Iandolo, Bruno

AU - Raus, Laura

AU - Riccio, Antonio

AU - Caputo, Antonio

PY - 1989/5

Y1 - 1989/5

N2 - Up-to-date unsatisfactory results obtained in multimodality treatments of malignant glioma have prompted the research of new therapeutic modalities with 'unconventional' modes of action. Lonidamine (LND) is a drug which reduces aerobic glycolytic activity in both human and experimental tumors. This effect mainly depends on the inhibition of mitochondrially-bound hexokinase (HK) which is present in large amounts in malignant cells. A Phase II study was conducted on patients with recurrent glioma; 12 patients were admitted to the study. Clinical side effects were moderate, necessitating a reduction of the dosage in only 1 case. The objective results were evaluated according to the indications of Levin. 2 responders and 3 cases of stable disease were observed out of 10 evaluable patients. The potential value of this new drug is discussed.

AB - Up-to-date unsatisfactory results obtained in multimodality treatments of malignant glioma have prompted the research of new therapeutic modalities with 'unconventional' modes of action. Lonidamine (LND) is a drug which reduces aerobic glycolytic activity in both human and experimental tumors. This effect mainly depends on the inhibition of mitochondrially-bound hexokinase (HK) which is present in large amounts in malignant cells. A Phase II study was conducted on patients with recurrent glioma; 12 patients were admitted to the study. Clinical side effects were moderate, necessitating a reduction of the dosage in only 1 case. The objective results were evaluated according to the indications of Levin. 2 responders and 3 cases of stable disease were observed out of 10 evaluable patients. The potential value of this new drug is discussed.

KW - brain tumor metabolism

KW - Lonidamine

KW - malignant glioma

UR - http://www.scopus.com/inward/record.url?scp=0024370465&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024370465&partnerID=8YFLogxK

U2 - 10.1007/BF00149384

DO - 10.1007/BF00149384

M3 - Article

C2 - 2666593

AN - SCOPUS:0024370465

VL - 7

SP - 103

EP - 108

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 1

ER -